Evidence map›Paper›PMID 24978044›Full record

ArticlePloS one2014

Differentially expressed plasma microRNAs and the potential regulatory function of Let-7b in chronic thromboembolic pulmonary hypertension.

Lijuan Guo, Yuanhua Yang, Jie Liu, Lei Wang, Jifeng Li, Ying Wang, Yan Liu, Song Gu, Huili Gan, Jun Cai and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 64 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Role of microRNAs in Hemophilia and Thrombosis in Humans.International journal of molecular sciences · 2020
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Lijuan GuoBeijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P.R. China; Beijing Institute of Respiratory Medicine, Capital Medical University, Beijing, P.R. China.
Yuanhua YangBeijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P.R. China; Beijing Institute of Respiratory Medicine, Capital Medical University, Beijing, P.R. China.
Jie LiuDepartment of Physiology, Capital Medical University, Beijing, P.R. China.
Lei WangBeijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P.R. China; Beijing Institute of Respiratory Medicine, Capital Medical University, Beijing, P.R. China.
Jifeng LiBeijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P.R. China; Beijing Institute of Respiratory Medicine, Capital Medical University, Beijing, P.R. China.
Ying WangBeijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P.R. China.
Yan LiuDepartment of Cardiology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P.R. China.
Song GuDepartment of Cardiology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P.R. China.
Huili GanDepartment of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, P.R. China; Beijing Institute of Heart, Lung and Vessel Disease, Capital Medical University, Beijing, P.R. China.
Jun CaiDepartment of Cardiology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P.R. China.
Jason X-J YuanDepartment of Medicine, University of Illinois at Chicago, Chicago, Illinois, United States of America.
Jun WangBeijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P.R. China; Department of Physiology, Capital Medical University, Beijing, P.R. China.
Chen WangBeijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P.R. China; Beijing Institute of Respiratory Medicine, Capital Medical University, Beijing, P.R. China; Department of Beijing Hospital, Ministry of Health, Beijing, P.R. China.
Beijing Chao-Yang Hospital · CNCapital Medical University · CNBeijing Anzhen Hospital · CNUniversity of Illinois Chicago · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) is a progressive disease characterized by misguided thrombolysis and remodeling of pulmonary arteries. MicroRNAs are small non-coding RNAs involved in multiple cell processes and functions. During CTEPH, circulating microRNA profile endued with characteristics of diseased cells could be identified as a biomarker, and might help in recognition of pathogenesis. Thus, in this study, we compared the differentially expressed microRNAs in plasma of CTEPH patients and healthy controls and investigated their potential functions. Microarray was used to identify microRNA expression profile and qRT-PCR for validation. The targets of differentially expressed microRNAs were identified in silico, and the Gene Ontology database and Kyoto Encyclopedia of Genes and Genomes pathway database were used for functional investigation of target gene profile. Targets of let-7b were validated by fluorescence reporter assay. Protein expression of target genes was determined by ELISA or western blotting. Cell migration was evaluated by wound healing assay. The results showed that 1) thirty five microRNAs were differentially expressed in CTEPH patients, among which, a signature of 17 microRNAs, which was shown to be related to the disease pathogenesis by in silico analysis, gave diagnostic efficacy of both sensitivity and specificity >0.9. 2) Let-7b, one of the down-regulated anti-oncogenic microRNAs in the signature, was validated to decrease to about 0.25 fold in CTEPH patients. 3) ET-1 and TGFBR1 were direct targets of let-7b. Altering let-7b level influenced ET-1 and TGFBR1 expression in pulmonary arterial endothelial cells (PAECs) as well as the migration of PAECs and pulmonary arterial smooth muscle cells (PASMCs). These results suggested that CTEPH patients had aberrant microRNA signature which might provide some clue for pathogenesis study and biomarker screening. Reduced let-7b might be involved in the pathogenesis of CTEPH by affecting ET-1 expression and the function of PAECs and PASMCs.

Indexed as

Gene Expression RegulationAdultCase-Control StudiesCell MovementCells, CulturedChronic DiseaseEndothelial CellsEndothelin-1FemaleGene Expression ProfilingHumansHypertension, PulmonaryMaleMicroRNAsMiddle AgedMyocytes, Smooth MuscleEndothelin-1MicroRNAsmirnlet7 microRNA, humanProtein Serine-Threonine KinasesReceptors, Transforming Growth Factor betaReceptor, Transforming Growth Factor-beta Type ITGFBR1 protein, human

Identifiers

PMID24978044
PMCPMC4076206
OpenAlexW2084175844

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.